Alefacept
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Intramaskularno |
| Identifikatori | |
| CAS broj | 222535-22-0  |
| ATC kod | L04AA15 (WHO) |
| DrugBank | DB00092 |
| UNII | ELK3V90G6C |
| KEGG | D02800 |
| ChEMBL | CHEMBL1201571 |
Alefacept je korišten za kontrolisanje inflamacije pri umerenoj do jake psorijaze sa formiranjem plakova. On ometa aktivaciju limfocita.[1] Alefacept je imunosupresivni dimerni fuzioni protein koji se sastoji od ekstracelularne CD2-vezujuće porcije ljudskog leukocnog funkcionog antigena-3 (LFA-3) vezanog za Fc (zglobin, CH2 i CH3 domain) porciju ljudskog IgG1.[2][3][4][5][6]
Reference
[уреди | уреди извор]- ^ „New drugs”. Australian Prescriber. 27 (101): 5. 2004. Архивирано из оригинала 24. 08. 2006. г. Приступљено 20. 8. 2006.
- ^ Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;Koo, J. Y.; Bagel, J.; Sweetser, M. T.; Ticho, B. S. (2006). „Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: Results from an open-label, multicenter study”. Journal of Drugs in Dermatology : JDD. 5 (7): 623—8. PMID 16865867.
- ^ Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. Krell, J. M. (јун 2006). „Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept”. Journal of the American Academy of Dermatology. 54 (6): 1099—101. PMID 16713481. doi:10.1016/j.jaad.2005.08.032.
- ^ Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. Parrish, C. A.; Sobera, J. O.; Robbins, C. M.; Cantrell, W. C.; Desmond, R. A.; Elewski, B. E. (април 2006). „Alefacept in the treatment of psoriatic nail disease: A proof of concept study”. Journal of Drugs in Dermatology : JDD. 5 (4): 339—40. PMID 16673801.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]- Alefacept Архивирано на веб-сајту Wayback Machine (18. јул 2014)
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
